NYSE$TEVA

Teva Pharmaceutical Industries ADR · Q3 2022 earnings

Q3 2022 earnings · · Investor relations

Briefing

delivered a solid third quarter amidst foreign exchange headwinds

Teva Pharmaceutical Industries Ltd. reported a decrease of 8% in revenues compared to the third quarter of 2021, with revenues of $3,595 million. GAAP diluted EPS was $0.05 and Non-GAAP diluted EPS was $0.59. The company generated $543 million in cash flow from operating activities and $685 million in free cash flow.

  • Revenues of $3.6 billion
  • GAAP diluted EPS of $0.05
  • Non-GAAP diluted EPS of $0.59
  • Free cash flow of $685 million

Headline financials

Total Revenue

$3.6B

Previous: $3.89B-7.5%
EPS (adj)

$0.59

Previous: $0.59+0.0%
Capital Expenditures

-$406M

Previous: -$409M+0.7%
Free Cash Flow

-$350M

Previous: -$117M-199.1%
Net Income

$56M

Previous: $292M-80.8%
Operating Income

$419M

Previous: $623M-32.7%
Gross Profit

$1.67B

Previous: $1.79B-7.0%
Cash & Equivalents

$2.23B

Previous: $2.05B+8.8%
Total Assets

$44.3B

Previous: $47.9B-7.5%
Stock-Based Comp

$25M

Previous: $26M-3.8%

Revenue & EPS history

Teva · Revenue · Quarterly

$3.6B

Q3 2022-7.5%vs Q3 2021
Beat estimate in 12 of 15 quarters(80%)
ActualEstimate

Revenue by segment

Teva · $1.54B total across 2 segments · Q3 2022

  • Europe
    $1.07B
  • International Markets
    $475M

Forward guidance

Teva revised its 2022 revenues outlook due to continued foreign exchange headwinds, but reaffirmed its operating income, Adjusted EBITDA, EPS, and free cash flow guidance.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2022

Historical avgQ3 2022

+0.3%

Avg return

Earnings day

+1.6%

Avg return

5 days after

+0.7%

Avg return

30 days after

51%

38 / 74 earnings

Positive

+27.1%

Q2 2022

Best reaction

-34.1%

Q2 2017

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-0.1%+11.9%+11.7%
Q4 2025+2.1%+9.2%+4.1%
Q3 2025+20.4%+18.6%+39.1%
Q2 2025+1.8%-5.1%+11.1%
Q1 2025+8.9%+11.4%+10.2%
Q4 2024-13.9%-19.4%-23.5%
Q3 2024-6.8%-7.5%-7.7%
Q2 2024+6.9%+1.6%+15.0%
Q1 2024+14.7%+21.0%+20.6%
Q4 2023+6.2%+5.5%+15.1%
Q3 2023-3.0%-2.4%+8.6%
Q2 2023+15.4%+16.2%+18.7%
Q1 2023-9.8%-11.3%-19.5%
Q4 2022-9.8%-5.4%-16.3%
Q3 2022-3.3%+3.7%-1.1%
Q2 2022+27.1%+30.5%+37.6%
Q1 2022-2.3%-8.1%+11.6%
Q4 2021+6.3%+2.8%-9.8%
Q3 2021-7.0%-1.7%-9.6%
Q2 2021+8.6%+10.4%+4.8%
Q1 2021+2.6%+4.2%+0.3%
Q4 2020-11.8%-13.2%-15.8%
Q3 2020-1.0%+4.5%+11.6%
Q2 2020+3.0%+0.6%-22.1%
Q1 2020+7.7%+9.0%+22.5%
Q4 2019+1.9%-0.9%-31.9%
Q3 2019+14.8%+18.6%+22.5%
Q2 2019+3.3%-0.6%-0.7%
Q1 2019-0.3%-4.1%-43.2%
Q4 2018-9.6%-6.0%-13.7%
Q3 2018+13.1%+15.6%+7.8%
Q2 2018-7.1%-2.5%-4.0%
Q1 2018-4.1%+1.6%+17.7%
Q4 2017-10.7%-11.2%-8.0%
Q3 2017-18.7%-16.6%+8.8%
Q2 2017-34.1%-16.2%-39.4%
Q1 2017+1.7%+1.3%-3.6%
Q4 2016+8.4%+9.4%+6.7%
Q3 2016-7.2%-6.0%-10.5%
Q2 2016+1.2%-6.2%-8.8%
Q1 2016+5.2%+1.7%+10.8%
Q4 2015-2.0%
Q3 2015-5.1%
Q2 2015-2.6%
Q1 2015+0.1%
Q3 2014+3.6%
Q4 2014+2.0%
Q2 2014-1.6%
Q1 2014+2.0%
Q4 2013-1.9%
Q3 2013-1.5%
Q2 2013-2.0%
Q1 2013+1.0%
Q4 2012+1.4%
Q3 2012+2.6%
Q2 2012-3.3%
Q1 2012-5.4%
Q4 2011+2.5%
Q3 2011+7.0%
Q2 2011+1.9%
Q1 2011+5.6%
Q4 2010+0.4%
Q3 2010+0.3%
Q2 2010-3.4%
Q1 2010+0.9%
Q4 2007+1.2%
Q4 2009+1.2%
Q3 2008-1.4%
Q3 2009-1.4%
Q2 2008-0.8%
Q2 2009-0.8%
Q1 2009-0.6%
Q1 2008-0.6%
Q4 2008-0.6%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro